143 related articles for article (PubMed ID: 37924714)
1. Cancer risk, disease-modifying therapy, and age in multiple sclerosis: A retrospective population-based cohort study.
Greenfield J; Metz LM; Khakban A; Llorian ER; Michaux KD; Traboulsee A; Oh J; Smyth P; Lynd LD; Bulloch AGM; Williams JVA; Patten SB;
Mult Scler Relat Disord; 2023 Dec; 80():105091. PubMed ID: 37924714
[TBL] [Abstract][Full Text] [Related]
2. Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
Gaindh D; Kavak KS; Teter B; Vaughn CB; Cookfair D; Hahn T; Weinstock-Guttman B;
J Neurol Sci; 2016 Nov; 370():13-17. PubMed ID: 27772741
[TBL] [Abstract][Full Text] [Related]
3. Risk of cancer among Finnish multiple sclerosis patients.
Hongell K; Kurki S; Sumelahti ML; Soilu-Hänninen M
Mult Scler Relat Disord; 2019 Oct; 35():221-227. PubMed ID: 31404761
[TBL] [Abstract][Full Text] [Related]
4. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
Al-Sakran L; Marrie RA; Blackburn D; Knox K; Evans C
BMJ Open; 2019 Nov; 9(11):e033599. PubMed ID: 31772108
[TBL] [Abstract][Full Text] [Related]
5. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
6. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
[TBL] [Abstract][Full Text] [Related]
7. Disease-modifying therapy use and health resource utilisation associated with multiple sclerosis over time: A retrospective cohort study from Alberta, Canada.
Balcom EF; Smyth P; Kate M; Vu K; Martins KJB; Aponte-Hao S; Luu H; Richer L; Williamson T; Klarenbach SW; McCombe JA
J Neurol Sci; 2024 Mar; 458():122913. PubMed ID: 38335712
[TBL] [Abstract][Full Text] [Related]
8. Radiologically isolated syndrome: A single-center, retrospective cohort study.
George IC; Rice DR; Chibnik LB; Mateen FJ
Mult Scler Relat Disord; 2021 Oct; 55():103183. PubMed ID: 34365315
[TBL] [Abstract][Full Text] [Related]
9. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies.
Burkhard A; Toliver J; Rascati K
J Manag Care Spec Pharm; 2021 Jul; 27(7):915-923. PubMed ID: 34185555
[No Abstract] [Full Text] [Related]
10. Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60.
Hua LH; Harris H; Conway D; Thompson NR
Mult Scler Relat Disord; 2019 May; 30():252-256. PubMed ID: 30851638
[TBL] [Abstract][Full Text] [Related]
11. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
[TBL] [Abstract][Full Text] [Related]
12. Secular trends in disease modifying treatment and expenditure in multiple sclerosis: A longitudinal population study in the north of Ireland.
Cromie D; Mullan F; Hinchliff C; Miller M; McVerry F; McCarron MO
Mult Scler Relat Disord; 2020 Oct; 45():102444. PubMed ID: 32799123
[TBL] [Abstract][Full Text] [Related]
13. Adherence and persistence to self-administered disease-modifying therapies in patients with multiple sclerosis: A multisite analysis.
Zuckerman AD; DeClercq J; Simonson D; Zagel AL; Turco E; Banks A; Wawrzyniak J; Rightmier E; Blevins A; Choi L
Mult Scler Relat Disord; 2023 Jul; 75():104738. PubMed ID: 37182475
[TBL] [Abstract][Full Text] [Related]
14. Cancer and multiple sclerosis in the era of disease-modifying treatments.
Lebrun C; Vermersch P; Brassat D; Defer G; Rumbach L; Clavelou P; Debouverie M; de Seze J; Wiertlevsky S; Heinzlef O; Tourbah A; Fromont A; Frenay M
J Neurol; 2011 Jul; 258(7):1304-11. PubMed ID: 21293872
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
Hua LH; Fan TH; Conway D; Thompson N; Kinzy TG
Mult Scler; 2019 Apr; 25(5):699-708. PubMed ID: 29557704
[TBL] [Abstract][Full Text] [Related]
16. Cancer risk for multiple sclerosis patients treated with azathioprine and disease-modifying therapies: an Italian observational study.
La Mantia L; Benedetti MD; Sant M; d'Arma A; Di Tella S; Lillini R; Mendozzi L; Marangi A; Turatti M; Caputo D; Rovaris M
Neurol Sci; 2021 Dec; 42(12):5157-5163. PubMed ID: 33791892
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
Mult Scler Relat Disord; 2022 Dec; 68():104220. PubMed ID: 36242804
[TBL] [Abstract][Full Text] [Related]
18. Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
Oleen-Burkey M; Cyhaniuk A; Swallow E
BMC Neurol; 2014 Jan; 14():11. PubMed ID: 24423119
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression.
Salavisa M; Serrazina F; Ladeira AF; Correia AS
Clin Neurol Neurosurg; 2023 Feb; 225():107612. PubMed ID: 36701940
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
